Position in CRIS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$11,835
+$11,643 QoQ
Shares Held
1,138
-90.2% QoQ
Ownership
0.054%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#19
of 36 holders
Holding Since
Sep 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CRIS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. CRIS ranks #162 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in CRIS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,835 | 22,760 | Shares | Sole | 2026-08-06 | |
| 2023-06-30 | $192 | 231,235 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $22 | 37,076 | Shares | Sole | 2023-05-12 | |
| 2022-03-31 | $79,000 | 33,316 | Shares | Sole | 2022-05-11 | |
| 2021-12-31 | $103,000 | 21,648 | Shares | Sole | 2022-02-14 | |
| 2021-06-30 | $499,000 | 61,893 | Shares | Sole | 2021-08-05 | |
| 2020-09-30 | $356,000 | 304,011 | Shares | Sole | 2020-11-06 | |
| No filing history on record for this holder in this stock. | ||||||